SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Intel shares fall back to April levels after losing over half their value in five weeks

Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast

Ground Up Ventures appoints Navot Volk as General Partner

After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems

Buzz

Most popular

Daily

Weekly

1

From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits

2

ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years

3

Israeli digital health company TailorMed acquired in $250 million deal

4

Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company

5

Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast

Sanofi

6 stories about Sanofi

CTech The growth conference Katie Kushnir Ventura

“People learn, people develop”: Sanofi Israel’s HR Head sees “only positives” in AI

10.06.25|Amy Shapiro

Speaking with CTech at the Israel Growth Conference, Sanofi Israel’s Katie Kushnir Ventura shared how the pharmaceutical giant is using AI to improve its operations and support employees through upskilling and easier access to digital resources.

מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman

Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.

ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman

Duvakitug signals a brighter future for the Israeli pharma giant.

מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman

Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.

Nucleai raises $33 million for spatial biology drug development platform

22.03.22|Meir Orbach

The technology developed at the Israeli startup allows better prediction of the patient's response to specific oncological treatment, saves on the ongoing process of testing different drugs and improves the chances of the development of new cancer drugs

עומרי שור מנכ"ל מדיסייף

Medisafe raises $30 million in Series C led by pharma giant Sanofi

25.02.21|Meir Orbach

The company expanded its platform in 2020 with the launch of Medisafe Care Connector, which digitally connects patients and doctors